Pricing Log in Create free account

ImmuCell Corporation (ICCC) vs Novogen Limited (KZIA)

ImmuCell Corporation and Novogen Limited are both Biotechnology companies. ImmuCell Corporation and Novogen Limited are of similar size ($94.2M and $92.4M). Novogen Limited has negative trailing earnings, so its P/E is not meaningful; ImmuCell Corporation trades at 117×. ImmuCell Corporation has the higher net margin (2.57% vs 0.00%) and the higher return on invested capital (7.84% vs 0.00%). Across the 14 metrics below, ImmuCell Corporation leads on 10 and Novogen Limited on 4.

Valuation

Metric ICCC KZIA Biotechnology median
P/E 116.78 n/m 10.26
P/S 2.92 — 9.18
P/B 2.85 n/m 2.05
Price to free cash flow 21.16 n/m 24.81
EV/EBITDA 14.15 1.46 0.65
EV/Sales 2.90 n/m 8.98
Earnings yield 0.86% (3.03%) (34.89%)
Free cash flow yield 4.72% 0.00% (24.52%)

Profitability

Metric ICCC KZIA Biotechnology median
Gross margin 40.32% 0.00% 65.16%
Operating margin 12.60% — 0.00%
Net margin 2.57% 0.00% 0.00%
Free cash flow margin 13.79% 0.00% 0.00%
Return on equity 2.57% 0.00% (50.12%)
Return on assets 1.69% 0.00% (45.60%)
Return on invested capital 7.84% 0.00% 0.00%

Growth

Metric ICCC KZIA Biotechnology median
Revenue growth (TTM) 8.49% — 6.26%
EPS growth (last fiscal year) 53.85% 63.24% 29.88%
Revenue growth, 5-year CAGR 12.50% 11.56% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ICCC KZIA Biotechnology median
Debt to equity 0.26 0.00 0.00
Current ratio 4.75 2.87 4.89
Net debt to EBITDA 1.19 0.30 1.01

Dividend

Metric ICCC KZIA Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ICCC KZIA Biotechnology median
Market cap 94.18m 92.35m 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack